4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Status:
Completed
Trial end date:
2013-05-07
Target enrollment:
Participant gender:
Summary
This is a four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group,
multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in
approximately 68 subjects with anemia associated with chronic kidney disease who are not
taking rhEPO and are not undergoing dialysis. The range of Hgb values for study eligibility
is 8.5-11.0 g/dL. Eligible subjects will be randomized in equal proportions to receive once
daily (QD) placebo or GSK1278863 0.5 mg, 2 mg or 5 mg in a double-blind fashion.